Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want the quick path to Biodesix’s most revealing disclosures? Investors tracking blood-based diagnostic innovators like Biodesix (BDSX) often need to pinpoint reimbursement updates, R&D spend on new lung biomarkers, or insider stock moves before clinical data drops. This SEC filings hub answers those questions in one place.
Navigate straight to the document you need—whether it’s the BDSX quarterly earnings report 10-Q filing that details Nodify Lung revenue, the BDSX annual report 10-K simplified for risk factors around FDA laboratory-developed tests, or the BDSX proxy statement executive compensation that links pay to diagnostic pipeline milestones. Stock Titan’s AI reads every page, producing concise summaries so you can scan complex tables in seconds. That means BDSX SEC filings explained simply, without losing critical nuance.
Real-time alerts flag BDSX Form 4 insider transactions, letting you monitor executive stock activity the moment it hits EDGAR. Need context? Our platform connects each trade to material disclosures so you understand motive, not just movement. You’ll also find:
- BDSX 8-K material events explained for coverage-decision news or new assay launches
- BDSX earnings report filing analysis that compares quarter-over-quarter margin shifts
- BDSX executive stock transactions Form 4 with historical trend charts
From understanding BDSX SEC documents with AI to drilling into BDSX insider trading Form 4 transactions in real time, this page keeps equity analysts, healthcare investors, and strategic partners informed—without wading through hundreds of pages.
Lightwave Logic, Inc. (LWLG) Form 4 filing: Director Craig Ciesla was granted 80,645 restricted stock units (RSUs) on 06/30/2025 under the company’s 2025 Equity Incentive Plan at $0.00 exercise price. The award vests in four tranches: 20,162 RSUs on 07/15/2025 and 20,161 RSUs on each of 09/30/2025, 12/31/2025 and 03/31/2026, contingent on continued service. Following the grant, Ciesla’s total beneficial ownership equals 80,645 RSUs, all held directly. No common shares were sold or disposed of, so the filing signals no insider selling pressure. While the grant is non-cash and non-dilutive until vested and settled, the shares will add modest dilution when they convert to common stock.
GS Finance Corp. is offering $1.08 million of Autocallable Contingent Coupon Equity-Linked Notes due 2028, fully and unconditionally guaranteed by The Goldman Sachs Group, Inc. The notes are tied to the performance of Palantir Technologies Inc. (PLTR) Class A common shares and form part of Goldman’s Series F medium-term note program.
Key commercial terms
- Face amount: $1,000 per note (aggregate $1.08 million)
- Issue price: 100% (trade date 30-Jun-2025; settlement 03-Jul-2025)
- Quarterly contingent coupon: $69.625 (6.9625% per quarter, up to 27.85% p.a.) payable only if PLTR closes at or above 60% of the initial price ($136.32) on the relevant observation date.
- Automatic call: If PLTR closes at or above the initial price on any quarterly call observation date from Sep-2025 to Mar-2028, the notes are redeemed at par plus the due coupon.
- Downside protection: 40% buffer. If the final price on 30-Jun-2028 is ≥60% of the initial price, holders receive par plus any final coupon. If below 60%, repayment equals par plus (index return × par), exposing investors to full downside beyond the buffer.
- Estimated value at pricing: ~$970 per $1,000, reflecting structuring fees and dealer margin; underwriting discount 2%.
- Secondary market: GS & Co. may, but is not obliged to, make a market; bid/ask reflects estimated value plus declining premium (initially $25).
- Credit: senior unsecured obligation of GS Finance Corp. with unconditional guarantee from The Goldman Sachs Group, Inc.; not FDIC insured.
Risk highlights
- Investors may receive no coupons if PLTR trades below the 60% trigger on observation dates.
- If PLTR falls >40% at maturity and the note hasn’t been called, principal loss is one-for-one with the stock’s decline.
- Limited upside: maximum redemption is par plus due coupon; investors do not participate in stock gains above par.
- Market value likely to be below issue price; liquidity limited; pricing sensitive to GS credit spreads, PLTR volatility and interest rates.
- Product complexity, dilution events, market disruption adjustments and discretionary determinations by GS & Co. add additional risks.
The prospectus supplement also details anti-dilution adjustments, default provisions, tax characterization (income-bearing prepaid derivative contract) and extensive hypothetical scenarios illustrating coupon and principal outcomes.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
What is the core business of Biodesix Inc?
How do Biodesix’s diagnostic tests support precision medicine?
What differentiates Biodesix’s diagnostic solutions from traditional imaging methods?
Who are the primary customers of Biodesix Inc?
Which industries does Biodesix serve?
How does Biodesix assist biopharmaceutical companies?
What methodologies does Biodesix use in its diagnostic tests?
How does Biodesix contribute to improved patient care?
